Welcome to today's conference call and webcast to discuss the merger between International Flavors and Fragrances and Frutarom as well as IFF's First Quarter 2018 Earnings. At this time, I would like to turn the call over to Michael DeVoe, Head of Investor Relations. Please go ahead.
Thank you. Good morning, good afternoon and good evening, everyone. Thank you for joining our call to discuss the combination of IFF and Friderone as well as IFF's Q1 2018 earnings results. As a reminder, this call is being recorded and the press release and slide presentation regarding today's news are available on the IR section of IFS and Frutarom's respective websites. Today's presentation will include non GAAP financial measures, which exclude those items that we believe affect comparability.
A reconciliation of these non GAAP financial measures to their respective GAAP measures is set forth in our press release that we issued today and is on our website. I would like to remind everyone that these statements being made that all statements being made during the call that relate to future results and events, including the proposed merger, are forward looking statements that are based on current expectations. Actual results and events could differ materially from those discussed here. Please refer to the information on the disclaimer slides in the presentation as well as the additional information contained in the regulatory filings for both companies. Presenting on the call today will be IFF's Chairman and CEO, Andreas Bibig Frutarom's President and CEO, Ori Yuhudai and IFF Executive Vice President and CFO, Rich O'Leary.
With that, I would now like to introduce Andres.
Thank you, Mike. This is an exciting day for both IFF and Frutarom. I'm going to take you through why we are so excited about the news we have announced today, and then I will cover the transaction terms. Ari will take you through Hootaroom's and its history at a high level for those that are not familiar. Finally, we will delve deeper into the compelling strategy and financial rationale for this transaction.
Lastly, Rich will conclude with a brief discussion of our strong first quarter earnings. So let's get started. We believe this combination will create a global leader in taste, scent and nutrition. This transaction is a win for both company's shareholders. Among the important benefits we expect to realize by combining with Frutarom, IFF will significantly increase its position in Natural Solutions.
We will also strengthen our exposure to fast growing small and midsized customer accounts, gain new opportunities in attractive and fast growing adjacencies, such as natural colors, enzymes, antioxidants and health ingredients and enhance our global reach. We will also be able to realize the benefit of strong talent comprising extraordinary employees globally. Overall, we have a tremendous opportunity to accelerate our growth, realize significant synergies and deliver attractive shareholder value. Moving on to the terms of this transaction on Slides 78. Frutarom shareholders will receive total considerations of US106 dollars $0.25 per share in a cash and stock transaction.
The transaction has an implied enterprise value of approximately US7.1 billion dollars And the consideration is a mix of 67% cash and 33% stock, which provides shareholders both immediate value and the ability to participate in the compelling upside of the combination. Notably, the transaction has a significant synergy potential. We expect to realize approximately $145,000,000 of run rate cost synergies for the 3rd full year. The transaction is expected to be neutral to adjusted cash earnings per share in the 1st full year and double digit accretive to adjusted cash earnings per share in the 2nd full year. The combined company is also expected to generate strong free cash flow.
As such, we expect to maintain our quarterly dividend consistent with prior guidance following the close of the transaction. We will suspend our share repurchase program to prioritize debt reduction. In terms of financing, we have a solid foundation a cash consideration expected to be financed with a combination of cash on hand, new debt raised and new equity of approximately US2.2 billion dollars We have bridge financing in place and the transaction is not subject to a financing condition. We are pleased that Aureus agreed to join us as strategic advisor following the close of the transaction to ensure a smooth transition. We are expecting to close in the next 6 to 9 months, subject of course to the receipt of regulatory approvals, a Frutarom shareholder vote and other customary closing conditions.
Affiliates of ICC Industries Incorporated, which owns 36% of Frutarom, have agreed to vote in favor of the transaction. Before I hand over the call to Ori to tell you a bit more about Frutarom, I want to thank him and his team for the extraordinary effort they have put forth on this transaction. Over the last several months, as we worked on the details of bringing our two companies together, I've had an opportunity to get to know him and his team a lot. Everything I have learned during the process has confirmed my tremendous respect for Frutarom and its team. And I have shared with Ory on many occasions Frutarom's expertise, reputation and record of performance is impressive.
We have long admired Frutarom, and I'm excited to be combining forces. Aure?
Thank you, Andreas, and it's a great pleasure for me to participate in this first call while we are aiming to combine these excellent two companies, IFF and Frutarom. I admire IFF since I joined this industry more than 33 years ago, and I'm sure that we all, including with my excellent colleagues, will admire the combined company going forward in the right way. In a way, if you allow me on a personal note, just shortly, I'm closing like 2 wheels or circles right now after this 33 years. I joined the company in 'eighty six with sales at that time $3,000,000 We were able to grow fast, double our company every 4 years, build a global company with 70,000 products sold to 30,000 customers in more than 160 countries. This is a great power to that we will be able to use together in the cross selling opportunity, while we combine the excellent product portfolio and technology of the 2 companies, of course, great support from the high technology of IFF that, of course, we didn't have access before.
So we truly build a global company combining fast internal growth above markets, 70 acquisitions added into the Frutarom portfolio and business over the years that enable us to jump from $3,000,000 in revenue to $1,600,000,000 today and hopefully more. The second circle that I can see is value creation. Frutarom became a public company about 22 years ago. Market cap was $13,000,000 $13,000,000 We are closing this circle today, which is only the beginning of the circle for me with the market valuation of over $7,000,000,000 So we were able to give some value creation to our shareholders with a great belief that I already always mentioned. We must find a way how we combine 1 plus 1 that equals 3 or 4 because I'm very weak in mathematics.
I believe and I'm sure that the combination of the two company will allow Frutarom together with IFF to grow faster. Frutarom itself as a standalone company had targets that were upgrades about 6 months ago following excellent acquisitions that we did to 2,250,000,000 dollars with EBITDA margin in our core business of above 23% before 2020. The 23% EBITDA margin, I'm sure, will be achieved much before. And I think the combination with IFF will enhance both the internal growth and the profitability following the synergies that were mentioned by my friend Andreas before and maybe he will come back to that later. I believe that part of Futurum's success was to see market trends before many of our competitors, in many cases before the food industry saw the competitors.
We build the company over the last 10 years on taste, on health, on natural, on the areas where billions of consumers want to see in their foods. And that enabled us to grow at a double rate than the markets we are operating in, with over 75% of our product today being natural products, much more than all our competitors. Another differentiation of Frutarom, definitely with IFF and with the other large companies that now we combine together to create a higher value will be with our specific approach towards customers. 70% of them, smaller, midsized local companies, Out of them, 1 third of the company's private label, private label sector in today's world is growing faster than many of the multinational IFF strength with the multinational. So we have now 2 strong legs, 1 with the multinational and one with the smaller customers and the private label primarily.
In the geography side, I think again, we are dealing with complementary combination of 2 companies that are strong in different areas. And again, this will allow us to grow faster than the way we were growing each company by itself up to now. The full solution of product that Frutarom can contribute with the cross selling are getting now a very nice booster with the IFS technology. And I'm very, very optimistic that using these synergies in the best way will allow us to grow faster than any other company in our area. In the last few years, Frutarom added some new technology into its portfolio through several acquisition, natural color, natural antioxidant, net infant nutrition, a fast growing business that we acquired through a company called enzymotech, natural cosmetics ingredient and we have more acquisition to do in that area, starter culture that are very profitable growing business.
I will not have the time to mention all of them. We'll have the time, me and Andreas, to talk to you and maybe give you some training about the Frutarom product to those that are less familiar with the Frutarom portfolio and how the combination of the two companies create, I believe, the best company in the industry. I take this opportunity to thank Doctor. John Farber, our Chairman, for his vision, support and trust and to thank our excellent employees that brought us to where we are now. On a personal note, I really feel lucky to be part of such incredible group, and I'm excited and thankful for Andreas to invite me to be part of that.
Thank you, Andreas, and the floor is yours, my boss.
Thank you, Ori. Let's go a bit deeper on the compelling strategy and financial rationale. As you can see on the Slide 11, this transaction solidifies IFF as a global leader in taste, scent and nutrition. We are uniting 2 industry leading innovative companies with complementary customers and capabilities and a talented and committed workforce. Ari and the entire Frutarom team have done an incredible job innovating and building their natural platform.
As a result, we will also become a global leader in this important arena and will be well positioned to meet the evolving needs of our customers and consumers. We will offer our customers a stronger, more differentiated portfolio of integrated solutions and capabilities. This will allow us to expand into attractive and fast growing areas, such as enzymes, antioxidants, health ingredients and natural colors. Our customers will have access to a comprehensive portfolio with more value added integrated solutions. With Frutarom, we will significantly increase our exposure to fast growing small and midsized customers, which dovetails perfectly with our new Tastepoint platform.
Slide 12 to 14 outline what the combined company will look like at a very high level. We will be positioned as a leader in natural capabilities, which will extend across our entire platform. Our customers will have access to comprehensive and differentiated integrated solutions with increased focus on naturals and health and wellness. This is consistent with the consumer trends we are all seeing. As an example, through their algae partnership, Frutarom has developed food supplements, but also cosmetic solutions that can be additive to our active ingredients platform.
For flavor, paprika combines the benefit of natural flavor and clean label color. In addition, rosemary extracts are powerful antioxidants offering health benefits to food and beverage solutions. On Slide 13, can see that the combined company is expected to have approximately US5.3 billion dollars of revenues in 2018, make it one of the largest players in the industry. Turning to Slide 14. Once the transaction closes, we will have a more diversified and more favorable revenue mix.
This shift also supports a more favorable growth profile. We will have new exposure to attractive adjacencies such as enzymes, antioxidants, health ingredients and natural colors, allowing us to expand beyond flavors. Importantly, the adjacencies FoodErwin brings establish competitive positions for the combined company in high value added categories with increasing expected market growth rates. Additionally, as outlined on Slide 15, by combining our R and D with the capabilities of Frutarom, we will be able to offer a full suite of value enhancing integrated solutions to customers of all size. For example, we're excited about the potential to combine our technical expertise in savory modulation and delivery system with Frutarom's savory solutions to strengthen our product offering to our savory customers.
Or in beverages, combining our flavor and sweetness modulation expertise with Frutarom's citrus capabilities, natural antioxidants and natural colors to build visually appealing, wholesome and nutritious beverage solutions. As a result, we will have products that are second to none. As you can see on Slide 16, it is not just the market growth rate that makes us excited. The combination also increases IFF's access to faster growing small and midsize customers. This is a key demographic subset within the fast growing markets just discussed that includes local and regional customers.
We will also gain a presence with fast growing private label customers. Slide 17 provides more details on the significant synergies we expect to achieve from this transaction. We anticipate $145,000,000 of run rate cost synergies for the 3rd full year after closing, was approximately 25% achieved in year 1. We expect the cost synergies to come from procurement, footprint optimization and streamlining overhead expenses. We have done our homework here and spent a lot of time looking at the business.
We are confident that these goals are very achievable. Cross selling opportunities and integrated solutions are expected to provide revenue synergies, providing additional value to the shareholders over time. As we've already discussed, we expect the transaction to drive strong earnings and cash flow accretion for the combined company. We anticipate double digit cash EPS accretion in the 2nd full year. Following the completion of the transaction, IFF is also expected to benefit from enhanced top line growth rates and a strong EBITDA margin.
When you take all of this together, we expect tremendous value creation opportunities. Importantly, we are committed to maintaining an investment grade credit rating and we'll prioritize deleveraging through our anticipated strong cash flow generation. Wrapping up, Slide 19 underscores how this combination with Frutarom fits with our stated strategy and our refreshed Vision 2020 plan. Our Vision 2020 strategy focuses on building differentiation, accelerating profitable growth and increasing shareholder value. We look to win where we compete and strengthen our position through developing pioneering firsts.
Our goal is to become our customer's partner of choice, and we will continue to look for ways to strengthen and expand our portfolio to tap into areas of expertise beyond the walls of IFF. This combination with Frutarom allows us to achieve all of these things. With that, I turn the call over to Rich O'Leary to discuss our Q1 results before we open the call up for questions.
Thanks, Andreas. I'd like to now turn your attention to a review of our Q1 2018 results. We have a few slides here to review. I'm pleased to report that we started off the year very well with robust growth across all of our key financial metrics. Our Q1 sales growth was strong as currency neutral sales increased 7%, which was comprised of 8% growth in Fragrances and 6% growth in Flavors.
Top line trends remain strong in both businesses with new wins, volume and pricing all contributing to growth. In Fragrances, we delivered broad based growth from all categories and regions. And in Flavors, we achieved growth in all categories and nearly all regions. In terms of currency neutral adjusted operating profit, our focus on driving greater efficiency throughout our business via cost and productivity initiatives continue to support overall profitability. When combining this with our strong top line performance, we had strong leverage in the P and L as operating profit and EPS both grew 12% on an adjusted currency neutral basis.
Turning to Slides 22 23. Flavors currency neutral sales increased 6% with growth coming from all categories led by strong improvements in savory and dairy. It should be noted on a 2 year average basis, growth continues to be strong at approximately 8%. From a regional perspective, of the 4 regions delivered growth led by double digit increases in both EME and North America. EME increased 11% on a currency neutral basis, led by strong double digit growth in Africa and the Middle East as well as mid single digit growth in Europe.
Growth was achieved across all categories, led by strong performance in dairy, beverage and savory. North America increased 10%, driven by strong new wins in beverage and dairy as well as double digit growth in Tastepoint. While the impact of the acquisition was not material on overall results, PowderPure added a couple of percentage points to growth in North excuse me. In Greater Asia, 2% growth on a currency neutral basis as double digit growth in India and China was muted by softness in Indonesia and the ASEAN region. And Latin America decreased 2% as mid single digit growth in the Southern Cone was more than offset by softness in Mexico and Colombia, which had strong year ago comparison.
In terms of profitability, PlayAmour's currency neutral segment profit grew approximately 15% led by volume growth, the benefit from productivity and favorable sales mix. Currency neutral segment profit margin achieved year over year margin expansion of approximately 190 basis points to 24.8%. Fragrance currency neutral sales grew 8% in Q1 as growth was broad based with contributions coming from all categories. Regionally, growth was led by double digit increases in 3 of our 4 regions. From a category perspective, fine fragrances improved 4% on a currency neutral basis.
Growth was led by strong double digit growth in Latin America and North America. In these markets, performance was driven by new wins as well as increases in volume. Consumer Fragrance grew 6% on a currency neutral basis. Growth was achieved in all categories, led by high single digit performance in home care, toiletries and hair care, as well as mid single digit performance in fabric care. The contribution of growth continues to be led by new wins with modest improvements in volumes.
Fragrance and Ingredients sales were up 18% on a currency neutral basis, driven by growth in nearly all regions, led by double digit growth in Latin America, North America and Greater Asia. Cosmetic active ingredients Currency neutral segment profit margin increased 60 basis points year over year, finishing at 19.4% in the quarter. As you see on the next slide, we were off to a strong start to the year, and that gives us added confidence in achieving our financial objectives for 2018. And while it's still early in the year, we believe we'll be closer to the upper end of our previously communicated sales and operating profit guidance range. Those ranges are 3% to 5% currency neutral sales growth, 5% to 7% currency neutral adjusted operating profit and 4% to 6% currency neutral adjusted EPS growth.
In terms of foreign exchange, while there continues to be fluctuations, we expect currency neutral translation to be favorable impact on sales of approximately 3 percentage points and add approximately 1.5 percentage points to adjusted operating profit and adjusted EPS, respectively. With that, let me turn it back over to Andreas.
Thank you, Rich. Let's summarize. We are very pleased with our strong start to 2018. Sales growth was robust with growth across both business units that when coupled with cost of productivity initiatives translated into strong currency neutral adjusted operating profit and EPS growth. We are more confident in our outlook for year as we expect to be towards the upper end of our previously communicated guidance range.
On this strong foundation, today's transaction comes from a position of strength. As we discussed, together with Frutarom, we anticipate delivering accelerated growth and offer our customers a stronger, more differentiated portfolio of integrated solutions, allowing us to expand beyond our core taste and scent businesses into Nutrition. We will drive differentiation via R and D, balance our customer base by emphasizing fast growing small and midsized customers and maximize our portfolio by expanding into fast growing and diverse adjacencies. Our partnership will result in value creation for our shareholders and even more opportunities for the talented employees of both companies. We could not be more excited about what the future holds for both of us.
Operator, let's open for questions.
Your first question comes from the line of Mark Strachan of Stifel.
Yes, thanks and good morning everybody. Congrats on the deal.
Hey, good morning, Mark. How are you?
I'm great for Monday morning.
Where's the report by the way?
It's already Monday afternoon in Israel. So I suppose that's a good way to start. I guess just thoughts broadly. So the deal gets you bigger in Flavors. How do you think about the sustainability of Flavors growth to remain ahead of Fragrances longer term?
I guess it has in recent years. So you're obviously expecting that to continue, but I guess I'd love to hear how you think about that. And then sort of related to it, thoughts on the strategic rationale for buying a business that has some overlap of competing within your core business, Flavors and Fragrances, I guess they're not completely a competitor with some smaller customer exposure. But how do you think about going into more traditional FNF versus going into an adjacent category at scale, enzymes, probiotics, something like that? So I guess thoughts on just overall growth rates would be helpful.
Okay. Yes, absolutely, Mark. So first of all, we would like to see that it's just an overlap on the classic and traditional flavors. But what we see is here a whole range of exciting adjacencies. And you well know with our Vision 2020, we have started to expand beyond flavors already and beyond fragrances actually with the acquisition, for example, of LMC where we went into active cosmetic ingredients.
By the way, we will strengthen with the Frutarom acquisition, the Active Cosmetics business as well because we have parts of it in it. And if you look at all the different markets, and actually we have one of the slides showing it very well, the adjacencies, the market growth of these adjacencies is a bit higher than in our traditional F and F. And we have some of these areas, which was really good profitability as well. So we are basically building beyond the traditional flavor business. That's the reason why we like to talk in the future about taste and nutrition as the 2 elements or segments where we are in.
We actually believe that the deal with Frutarom is very complementary, actually in many regards, in terms of the portfolio and the technologies, in terms of the geographic exposure because we are filling in some gaps we are having, for example, in Eastern Europe, where Frutarom is very, very, very, very strong. So that's helping us a lot. So for me, it's a very natural prolongation of our Vision 2020 strategy and fits exactly into that. That's the reason why Ori and myself thought this combination is something which is just unbeatable because it fits so well together. So we are a bit stronger on the taste and not on the taste and nutrition side, but we believe that's really good.
Rich, do you want to Yes.
I mean, Andres and Maura, I mean, for me, I think it is very it's a great opportunity. It shifts the overall mix when you think about it. It's going to be favorable in terms of accelerating growth for the combined companies. From a business standpoint, we know the overall markets on the flavor side are higher than the fragrance side, but both businesses remain very attractive and very profitable. It helps from a category standpoint that Andreas talked about that we're getting access to and a foundation to build upon some of the faster growing adjacencies that we've targeted and saw real opportunities as part of Vision 2020.
And then the access to the faster growing local and regional customers, all those things are going to be positive for the overall growth profile of the company.
And the good thing on the customer side is the overlap is not that big. So it actually helps us for the cross selling quite tremendously because we can sell our technology to food at home customers and vice vice versa. So we believe that will create a lot of value going forward as cross selling.
Great. And just following up on the last point. So how confident are you in retaining the customers? I guess if you can give more of a specific percentage of customer overlap, that would be helpful. And just sort of another broader question as it relates to customers.
So your gross margins were a bit better in the quarter than I think most would have expected certainly us. Has the pushback on the pricing that you talked about last fall subsided? And in doing a deal like this, do you think that helps get more scale? Just how do you think about the puts and takes in dealing with your customers on a go forward basis? Obviously, you're offering them more solutions, but they're all still under pressure on their own to hit their own earnings algorithm.
So if you look at the customer base, Frutarom is covering around about 30,000 customers. We cover around about 3,000 customers. So there's actually, as I said, not a lot of overlap. We believe that the danger is that we are losing important customers is very, very little. We don't think that will happen.
The good thing as well on the Frutarom side is because they are standing on so many legs with so many different customers. There's not this big customer. If we lose it, it will put the deal into jeopardy. I think it's actually a very good risk mitigation for all of us that they have such a wide customer base and we will now go really into the targeting how we do the cross selling in the best possible way. On the pricing?
I mean, I think my first comment I would say, when you look at the categories, I mean, there's not there are in a lot of ways, Frutarom, their business where there is overlap from a customer standpoint. So a lot of that's coming in categories that we don't have today. So again, I feel like the risk of overlap is quite low. From a pricing standpoint, I mean, it's a market environment, and we have to manage through that the way we do day in, day out every day. Yes.
Okay.
Your next question comes from the line of Lauren Lieberman of Barclays.
Great. Thanks. Good morning.
Good morning, Lauren.
First thing I wanted to ask about was just integration. So my understanding is Frutarom has been, as we know, very, very active on the M and A front. And so as you're thinking about synergies and integration, I wanted to know, 1, how much of the $145,000,000 is sort of kind of get reworked because now integration maybe means something different as you're integrating some of those deals into a bigger sort of infrastructure vis a vis ISS? And just kind of visibility on timing of those pieces.
So, Lauren, thank you for the question. And indeed, the integration is of utmost importance. First of all, we have started already with Ori and the Frutarom team to identifying what are the areas and that's how we came up with $140,000,000 to $45,000,000 And we are actually very confident that we can achieve it. And we look and we look during the DD from our point of our vantage point on the integration. And we believe that we have already a good idea and a good plan in place.
We will bring up an integration office, which is meant with people from both companies, with one of our high ranking IFF executives to lead this team for the next 1.5 or 2 years to really make it a priority for us. Actually, we have even set up a Board Integration Committee, which is led by as a Chairman by Marcelo Bottoli to make sure that we have the right focus on it. So I believe we are very well prepared. And then we should not underestimate that what Frutarom has done in the last couple of years is a lot of work on integration already. So we are counting here on a very experienced team, which can support us to bring this all on board.
Yes. I think from my standpoint, Lloyd, I mean, we really did start with a clean sheet of paper and said, okay, let's look at the 2 organizations, where are their opportunities, whether it's from a technology standpoint, whether it's from a sourcing standpoint, manufacturing footprint, the overhead expenses. And I think we feel very good about and confident about our ability to deliver on that and leverage, as Andreas said, leverage the talent and the expertise on both sides of the business.
Your next question comes from the line of Mike Sison of KeyBanc.
Hey, guys. Congratulations on a really nice deal there. In terms of the accretion potential in year 2, can you maybe talk through what type of growth you expect the Frutarom to generate in that year? How much of the synergy would come in year 1 or in year 2? And then maybe frame up the I guess your long term goal if you grow EPS organically, I add double digits or 10% or something that would be kind of a strong double digit mid to high teens EPS growth in year 2.
Is that the way to kind of think about it? Thanks.
Mike, there's a lot there. I'm not sure I can write that fast. Look, I think from a synergy standpoint, the cost side, as we talked about in our previous materials, we think about 25% of the synergies will come in year 1. There will be probably between 70% 75% in year 2 and then fully in year 3. Year 2 year 1, we believe we're basically going to be neutral from a cash EPS standpoint.
And as we said earlier, double digit increase in double digit improvement on a cash basis in year 2. From a top line standpoint, there is again, this is an attractive business. Frutarom has had a consistent growth trajectory on an organic basis for last 3 years, growing faster than we have been growing. On top of that, there's benefits associated with their M and A program, which has been a crucial part of their business strategy. So I think on an absolute basis, combining organic growth and some of the carryover impacts of their M and A program will have higher growth in year 1 and the normal growth at the higher end of our range going forward.
Your next question comes from the line of Faiza Alwy of Deutsche Bank.
Yes. Hi, good morning and congratulations. Good
morning, Faiza.
So I have two questions. One is just can you talk about how much overlap there is in North America specifically because I know that's where you've made an effort to target some of the smaller and medium sized customers. And to the extent there is sort of how do you plan to run the business together in North America and then just globally post deal closure? And then my second question is just on seems like Frutarom's gross margins and EBITDA margins are a bit lower than yours. Do you see that as an opportunity?
Or do you think that's a function of the categories that they are in versus that you're in?
Faiza, thank you for the question. I'll take the first part and then reach the second one. So actually, North America, the overlap is very, very, very small, how we see it, But it will fit actually very, very well into our business, in particular with the taste point we have set up here. So we will make now this part of the business super, super strong, and it will help us in our home market actually a great deal. Rich?
Yes. Faiza, to my point, looking at the margins, I mean, first of all, Frutarom has had a tremendous impressive record of growing the business but expanding margins. It's a very strong business, and we're extremely pleased to have that opportunity combined the 2 companies. I think some of the opportunities and the differences reflected in the margin is reflected in synergy opportunities that we already discussed earlier. Another piece of it can be mix related also.
Your next question comes from the line of Adam Samuelson of Goldman Sachs.
Yes. Thank you. Good morning, everyone. I guess my first question would be just around kind of what pro form a growth, margins, capital intensity of the business. And as you think about what the pro form a organic revenue growth would look like for the combined business, I mean, acquisitions post close, I'd imagine would become a less kind of imminent strategic priority.
And then on the capital intensity portion, what the working capital do you see any in working capital post the deal? I think the cost synergies was just a cost number and there wasn't any identified cash synergies. And then one quick follow-up on the quarter. You exceeded kind of your range on growth on kind of all metrics, but the guidance range was left unchanged. Could you talk about drivers of implied deceleration over the balance of the year?
Thank you.
Okay.
So Adam, I mean from a growth perspective, I gave you some comments on the last one amount in the direction where we are. I'm not going to get into specifics. From a margin potential, I think when you look at the 2 businesses, add on the synergies, we feel like we're going to be well positioned to be competitive at the high end of the market in terms of overall EBITDA margins. From a capital intensity standpoint, I think there's opportunities as we combine both organizations to drive improvements on an overall basis in terms of our working capital performance. It's going to help drive the cash flow over the next 5 years.
It's going to help drive the deleveraging. That's important to part of our overall strategy. From a CapEx standpoint, I think as we look at the overall organization, over time, it will come down. Again, we have to work through some of the integration work will require some one off CapEx. And then so there'll be some included in our estimates of included in our estimates of the cash flow models over the next couple of years is some CapEx necessary to drive the synergies from a manufacturing standpoint.
But overall, this is a very strong business. Both businesses are extremely profitable, strong cash generation, and that's going to get us where we need to be to grow the business and also deleverage on an accelerated basis. From an earnings standpoint in our guidance, there is an implied difference between first half or Q1 first a strong start in Q1. As we've talked about on the last call, number 1, the second half comps in the last year become much, much stronger compared to the first part of last year. We feel confident about our ability to get to the higher end of the range from a growth, from a sales and operating profit standpoint.
As I've talked about on the prior call, there's still a lot of movement in the industry in terms of demand, inventory impacts. And so I think we're being appropriately cautious at this point in terms of our guidance for the full year.
Your next question comes from the line of Brett Hundley of Vertical Group.
Hey, good morning, guys. Thanks for the question. I just had 2. The first one is a simple one. I was just curious if Root will continue its M and A strategy during the next few months?
I know their pipeline is very full, so I just wanted to comment on that. And then secondly, Andreas, in our opinion, fruit grows the way that it does, because of its, what I'll call a satellite approach and heavy levels of decentralization. So their culture seems very different than yours. And honestly, when we speak to other companies in the industry, many times they say that they don't even know when they're going up against Frutarom in a bid or something like that just because of all their disparate acquisitions over time. So it does seem like you really have your work cut out for you in realizing your synergy target, which is a pretty high target to begin with.
Do you feel like you're being aggressive with the timeline of synergy realization? And can you just delve back into the confidence that you have in realizing that target and the work that you've done? Because again, I think some of us are just thinking, wow, fruit has all these different businesses and IFF may potentially have some real work ahead of it. Thank you.
So let me start with
the It's an easy one.
From an M and A standpoint, I mean, as I made a comment earlier, I mean, the M and A part has been an important part of the growth strategy and the vision for Frutarom. It's a key core competency of the Frutarom Organization. We want to continue to leverage that and help drive the growth of the combined companies. We are confident given the strong cash flow of both businesses and the industry as a whole that we can continue to execute on the M and A platform while aggressively deleveraging the company.
On the second question, we believe that both companies have an entrepreneurial culture and that is a pretty, pretty good alignment. So we don't believe that we have an aggressive timeline on the cost synergy realization. So we feel real good about this. And if you think what we have started now, let's say, a year, 2 years ago with our TastePoint experiment in the U. S, It basically shows how you can deal with these smaller companies.
Remember, we brought David Michael and Ottens and we have combined them into the Tastepoint as an outreach or platform for the more regional smaller or midsized customers. I believe that we have already some expertise and that we also know when you build this platform, for example, how do you basically separate the traditional IFF business with the big customers, but still make sure that companies like Face Point and now in the future, the Frutarom subsidiaries will get access to IFF technology. And that's the part of cross selling, which will create a lot of value going forward. And I believe that's a tremendous opportunity.
Your next question comes from the line of John Roberts of UBS.
Thanks and congratulations to both companies.
Yes. Good morning, John.
Thanks, John.
Could you comment on margins on the 25% of sales that aren't flavors? I assume trading is below average and natural colors, enzymes and antioxidants are above average.
Yes. I think that's the right way to think about it. I mean, the trading business is very much almost like a distribution type. So the margins are low, but it's a key value value added service that the Frutarom business provides to its customers.
And then how do you plan on reporting the non flavors part of Frutarom? I think sometimes the way companies report kind of tells us a little bit about how they'll manage the business as well. Will you roll it into flavors like you do in Lucas Meyer's in fragrances? Or will you put it over with the fragrance ingredients? Or how do you plan to handle that?
Yes. What we will do over the next couple of months until the closing is that we will come up with the right structure for the business going forward, which positions us to capture the value as best as we can. And then we will basically decide on the reporting structure here as well. And you're right, John. There are a couple of ways to go and now we have much more businesses.
We have to look how we do it in the best possible way to make sure also that we support the cross selling.
Yes. Thank you.
Your next question comes from the line of John Feeney of Consumer Edge.
Good morning. Thank you very much.
Good morning.
Andreas, we've talked for a while about one of the first questions I
ever came up with, I don't know if it
was a good one was why mergers between the largest flavor and fragrances houses in the world don't really make sense? And I was referring to Juvenile and Symrise. And Firmenich, there's discrete capabilities, there's overlapping customers. What are there aspects of this transaction that suffer from that? Like do you are there major overlaps where you have commented on the existing customer base?
There's something special about Frutarom and IFS capabilities that make that a lot less of a problem? And Ori, if you wouldn't mind, if I could ask you, what makes IFS certainly a great company, a lot of growth for all the reasons you outlined, it's been incredibly would accelerate any flavor houses growth. Why IFF as a partner owner colleagues going forward? Thank you.
So let me start with it and then hand it over to Ori. So for us, the great thing about this and why we believe is the best fit you can find in the industry is that we don't have these major overlaps either in the customer base, which basically broadens the customer base of the new company and also makes us much, much stronger on the naturals, which is a very great strategic fit for us. So Ori, why IFF?
Many reasons. First, he's the guy that talked before me, Andreas, that I think, in a way, got in love with him and decided to go with him, even though we had other bidders and other interested parties that were less attractive to Frutarom. But on a more, I would say, serious note, even though the previous one was the truth, I mean, look, there aren't too many flavor or specialty fine ingredients that are relevant in this space. Financial investor is not interested interesting for Frutarom because it's not money that we are looking for. I strongly believe, as Andres correctly said, that here we really talk about the combination of 2 companies that are operating in different fields in 80% of the cases.
If you talk about savory solution for the processed meat, processed fish, ready meals, Frutarom build over the last 12 years, a leadership position in that area and that's not the strength of IFF. So here, this will be completely complementary to IFF, but we will use the excellent capabilities of IFF in flavor creation of specialty savory ingredients. When you go to natural products, again, Frutarom build over the last 10 years, an exciting product portfolio, I. E, natural color, natural antioxidant, natural cosmetics ingredients that, of course, will go together with IFF and give them a very nice boost with high end technology of products coming from algae or coming from extracts and other application. The difference in customer portfolio, 75% of Frutarom customers meet local, midsize with a special emphasis on the private label.
I believe that was not the focus of IFF correctly so as a large company. And I'm sure that between Adriaan and me and the management, we will know how to not to lose customers and really use both expertise to create the 1 +1equal4. So it's the combination of the differentiation in customers, differentiation in products and then talk about geography. Frutarom is very strong in some geography where I believe IFF historically were not very strong. I will give example.
Central and East Europe, very strong growth for Frutarom, but not where IFF invested before. Frutarom is very, very weak in Asia. IFF is strong in Asia. And now we have both Frutarom portfolio and IFF portfolio to go to the same customers. Frutarom acquired and Zimotech with the infant nutrition business, that's not a business that IFF has, but IFF has many large customers that are using or might use this type of technology.
So we are going to a new area of basic nutrition ingredients that enhance our position. Frutar acquired a company called Tara with unique amazing technology to drive fruits within less than 1 minute in an authentic way, no flavor, no sugar added. This is extremely interesting for many customers, for example, in the United States, nutritional bars, many other areas, large customers that are IFF customers, not necessarily Frutarom customers. So the entrance into these customers will be much higher. I can continue to talk about it for another year, but really this is about creating value and growth, and I strongly believe that this is what we are going to achieve together.
Your next question comes from the line of Gunther Zechmann of Bernstein.
Hi, good morning.
Look, you've spoken a lot about the synergy potential and the margins. Can I just ask about the returns from the Frutarom acquisition for IFF? You've got this target to earn your cost of capital within a 3 to 5 year time horizon. And I think all except one acquisition were within that time frame. Where does Frutarom in your projections stands on return on invested capital basis?
That's the first one. And the second one on sales synergies. You've got the €145,000,000 in cost synergies by the 3rd full year of acquiring Frutarom. You've spoken a lot of the sales synergies, but can you put some numbers on that? That would be very helpful.
Thank you.
Okay. Thanks. Let me start with the first one from a return standpoint. Yes, this given the size and the transformative nature of this deal, I think we're looking at it 2 different ways. 1, on a cash basis, again, focusing on how strong the business both companies are, We're probably going to we project that we're going to get the cost of capital returns between year 5 year 6 on a cash basis.
On a GAAP basis, probably another year later and one additional year. So we still feel very good about the return profiles of combining the 2 companies and certainly the long term value creation that combining the 2 companies provide. From a synergy standpoint, again, we're focused on the cost synergies. We do believe that there's substantial opportunity out there from a cross selling standpoint, but don't we're not going to comment specifically on what that value
is. Your next question comes from the line of Fenton Ryan of Berenberg.
Hi, Fintan. Hi, Fintan.
Hello? Next question, operator.
Your next question comes from the line of Patrick Lambert of Raymond James.
Hi, good afternoon. Congratulations for the interesting combinations this year. Two questions for me, I think a bit financial related to a transaction. The cost of integration of a business is you haven't mentioned it and questions around the IT systems. Anything that you think is going to be a bit challenging in terms of integrating Frutarom to IFF.
Linked to that also again for, I guess, Richard, the tax impact, what can you actually deduct? I know it could be a good driver for value if you can deduct a lot of the intangibles there? And finally, I think you answered the overlap of clients, but a very quick one on Q1 results in terms of the 8% fragrance growth in particular? How much was pricing versus volume overall for IFF and in fragrance in particular? And are you a bit more in could you a bit more precise your view on the Sitral disruption and impact in Q2, Q3 and the remainder of the year?
Have you got a bit more details on that, a bit more granularity on it? Thank you.
Maybe I take the last question first. So on Q1, as you were saying, very strong growth on the fragrance side. There was not much pricing built in, in this in the Q1. So it's volume, which is great. On the Citroen situation, you probably see that the BASF is coming back to to deliver what our customers need.
And to deliver what our customers need. And we're optimistic here going forward. So that's where we are, and we are in a very good position. Now I'll hand over to Rich on the financials.
Okay. Thanks, Andres. Yes, just one quick comment. I mean, on the fragrance growth, it was predominantly volume and commercial performance, new wins, but there was pricing in there. So it was helpful.
In terms of citral, I do think it's going to be heavily the impact, as Andres said, we're on target with our previous estimates. We still believe that's appropriate. I think we'll see the biggest impact in Q2 and Q3, again, depending upon what happens from their side. From a cost standpoint, the cost ballpark. It's a combination of cost.
As I mentioned earlier, there's some capital in there that we believe is going to be necessary to be spent in order to achieve the synergies. From a financing standpoint, it's still pretty early in the process. I think there are opportunities, and we'll structure the deal within the company in order to optimize that from a standpoint, look at where the business operates, where the cash flows are generated. So we still have some opportunities there to work through, but I think we're confident in our ability to help to have that drive the double digit returns that I talked about earlier in year 2 on a cash basis. And in tax?
No, I mean, it's part of as I said, we still have to go through the details and work with the fruit of our own team in terms of how to optimize the structure that allows us to generate get the cash from where it should generate it to where we need to do to pay down the debt and work through the specifics of the tax implications associated with that.
Your next question comes from the line of Fenton Ryan of Berenberg.
Hello. Can you hear me now?
Yes. Yes. Very well, Fenton.
Yes. Sorry, guys. It's the bank holiday here. So just away at my desk at the minute. I think most of my questions have been answered.
But I'd just like to get a sense that within the synergy plans or the integration going forward, do you plan on any asset disposals, particularly around some of the trading and marketing operations within Frutarom? And or within the integration as well, I know Frutarom has acquired majority stakes in a number of entities. Is there any sort of change of control provision in those deals so that you need to buy out some of the minorities as well taking on just the bulk Frutarom equity?
No, actually we're not planning to dispose any of the businesses, at least not big parts. And we go forward with the businesses where Frutarom has entered into agreements and has majority parts of the business. So I think that will be business as usually for Frutarom and for us going forward as well.
Yes. I think as I mentioned earlier, I mean, the trading business is a value added service that the Frutarom management team believes is central in terms of their relationships with the customers. Again, we'll look at potential asset sales as we work through these integration process, but it's too early to say.
Your next question comes from the line of Patrick Rafais of UBS.
Hi, and thank you for taking my question, please. From a technical point of view on the contract you have, is there a break fee in case the transaction doesn't happen? And can you elaborate a bit on what happens to or with the other interested party that was mentioned to be involved? Why was that an inferior solution? And lastly, you talked a lot about complementarity of the business and very little overlaps.
And so does that mean that you do not foresee any antitrust related issues in any of the key markets in this transaction? Thank you.
So let me start with the last piece. We certainly have to work with the regulatory authorities on the antitrust. But in our initial assessment, we believe it will be positive and benign. So we don't expect any extra hurdles here. And then I hand over to
Yes, there is included in the sale and purchase agreement a breakup fee. It's standard and it's consistent with industry standards.
And on the other interested party, I think Ori gave the reason why he believes that IFF is the best partner in the industry. Okay.
Your next question comes from the line of Subkee Moze of Kempen Capital Management.
Yes, good morning. Thank you very much and congratulations on the deal. I have one question. I heard somebody referring to that he was not that good at mathematics, but I'm now beginning to doubt myself. I was wondering if you could give a pro form a leverage for the deal because I saw somewhere of 3.7, but I'm not exactly sure how you arrived at that specific number.
Thanks.
Thank you for the question, Rich.
Yes. It's 3.7% on a simple basis in terms of just looking at net debt over the EBITDA on a run rate basis. And then we expect, as I said, to get delivered quickly over the next 18 to 24 months and probably get down to less than 2.5 times over that period.
Thank you. At this time, there are no further questions. I will now return the call to Andreas for any additional or closing remarks.
No, it's an exciting day for Frutarom and for IFF. We're making really good progress. And I would like to thank Ori as well for participating in the call. I think it worked out very well and the 2 of us believe it's a real strong combination and it's more than 1.1 plus 1 is 3 or 4. I think going forward, it will be a great future for both companies.
Thank you.